<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(10)</volume><submitter>Moghnieh R</submitter><pubmed_abstract>In this study involving a cohort of employees of the National Airline company in Lebanon, we assessed humoral immunity levels and the effectiveness of two COVID-19 vaccines, Gam-COVID-Vac versus BNT162b2, after two doses and after a homologous and heterologous BNT162b2 booster, in addition to the impact of hybrid immunity. Vaccine effectiveness (VE) was retrospectively determined against laboratory-confirmed SARS-CoV-2 infection during the periods of Delta and Omicron variants' predominance, separately, and was calculated based on a case-control study design. The humoral immune response, measured by a SARS-CoV-2 anti-spike receptor-binding domain (RBD) IgG titer, was prospectively assessed after the aforementioned vaccination schemes at different time points. This study showed higher effec</pubmed_abstract><journal>Vaccines</journal><pagination>1596</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9607825</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants.</pubmed_title><pmcid>PMC9607825</pmcid><pubmed_authors>Moghnieh R</pubmed_authors><pubmed_authors>Bizri AR</pubmed_authors><pubmed_authors>El Hajj C</pubmed_authors><pubmed_authors>Sayegh MH</pubmed_authors><pubmed_authors>Jbeily N</pubmed_authors><pubmed_authors>Abdallah D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants.</name><description>In this study involving a cohort of employees of the National Airline company in Lebanon, we assessed humoral immunity levels and the effectiveness of two COVID-19 vaccines, Gam-COVID-Vac versus BNT162b2, after two doses and after a homologous and heterologous BNT162b2 booster, in addition to the impact of hybrid immunity. Vaccine effectiveness (VE) was retrospectively determined against laboratory-confirmed SARS-CoV-2 infection during the periods of Delta and Omicron variants' predominance, separately, and was calculated based on a case-control study design. The humoral immune response, measured by a SARS-CoV-2 anti-spike receptor-binding domain (RBD) IgG titer, was prospectively assessed after the aforementioned vaccination schemes at different time points. This study showed higher effec</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-04-03T21:29:58.055Z</modification><creation>2025-04-03T21:29:58.055Z</creation></dates><accession>S-EPMC9607825</accession><cross_references><pubmed>36298460</pubmed><doi>10.3390/vaccines10101596</doi></cross_references></HashMap>